KRT18 and COVID-19: The K18-hACE2 mouse model (transgenic expression of human ACE2 (hACE2) under a cytokeratin 18 promoter) offers a stringent system for testing the efficacy of DAAs and HDAs against severe disease and mortality after SARS-CoV-2 infection24.